FDA Expands Nexavar Use in Refractory Thyroid Cancer
The FDA approved the expanded use of Nexavar (sorafenib; Bayer HealthCare and Onyx) for the treatment of locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer.
The safety and effectiveness of Nexavar were established in a clinical trial involving 417 participants with locally recurrent or metastatic, progressive differentiated thyroid cancer that does not respond to radioactive iodine treatment.
Treatment with Nexavar increased the length progression-free survival by 41%. Half of patients receiving Nexavar lived without cancer progression for at least 10.8 months vs. at least 5.8 months for patients receiving placebo.
For more information call (888) 842-2937 or visit Nexavar-US.com.